ABOS ACUMEN PHARMACEUTICALS INC
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 7 analyst firms say about ACUMEN PHARMACEUTICALS INC: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
6 rated views · 7 analyst/firm records · 7 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Fewer than 4 price targets in the last 6 months (2)
- Russell 2000 · Safest consensus · 6MNot scored · Fewer than 4 price targets in the last 6 months (2)
Recent analyst activity · last 90 days
Our tracked history has 11 reports on ABOS from 6 analyst firms in the last 90 days (8 firms in the past year).
Comparing each firm's latest target with its previous one: 1 lowered it, 1 left it unchanged and 2 have their first observed target in the past year.
Ratings, latest available report against the previous one: 0 upgrades and 2 downgrades.
Latest observed target change: BTIG Research lowered its target from $8.00 (set 26 Mar 2026) to $1.00 on 2 Nov 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| BTIG | Thomas Shrader | Buy | 16 Sep 2026 | Conflicting reports · excluded |
| Cantor Fitzgerald | Pete Stavropoulos | Sell | 30 Oct 2026 | — |
| Citigroup | Geoff Meacham | Hold | 30 Oct 2026 | Conflicting reports · excluded |
| Lucid Capital Markets | Dev Prasad | Hold | 2 Nov 2026 | 1.00 USD |
| Stifel | Unnamed analyst | Hold | 30 Oct 2026 | 1.00 USD |
| Weiss Ratings | Unnamed analyst | — | 30 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 03:45 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.